Medpace Holdings President & CEO Sells Over $30.3M in Common Stock

Executive Summary

On October 1, 2026, August J. Troendle, President, Chief Executive Officer, Director, and 10% Owner of Medpace Holdings, Inc. ($MEDP), reported open-market sales totaling 48,667 shares of common stock. The transactions were executed over two consecutive trading days (September 29 and September 30, 2026) for an aggregate gross consideration of approximately $30.32 million.

Transaction Details

• September 29, 2026: Sold 26,701 shares at a weighted-average price of $621.02 per share (individual trades ranged between $620.00 and $622.35), generating $16,581,855.02.
• September 30, 2026: Sold 21,966 shares at a weighted-average price of $625.47 per share (individual trades ranged between $620.105 and $628.08), generating $13,739,073.02.
• Aggregate Volume & Value: 48,667 shares at an overall volume-weighted average price of $623.03, totaling $30,320,928.04.

Ownership Structure & Context

• Order Execution: Footnote disclosures specify that the sales were executed pursuant to limit orders placed during an open trading window rather than an established Rule 10b5-1 trading plan.
• Remaining Holdings: Following these transactions, Dr. Troendle directly holds 338,225 shares of common stock. In addition, he retains indirect beneficial ownership of 4,733,019 shares through Medpace Investors, LLC, over which he holds sole voting and investment power.
• Significance Assessment: High significance due to transaction scale (>$30M) and the reporting person's position as Founder, CEO, and primary controlling stakeholder, though the shares sold represent less than 1% of his combined direct and indirect equity stake.